hVIVO plc (OPORF)
OPORF Stock Price Chart
Explore hVIVO plc interactive price chart. Choose custom timeframes to analyze OPORF price movements and trends.
OPORF Company Profile
Discover essential business fundamentals and corporate details for hVIVO plc (OPORF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Jun 2020
Employees
301.00
Website
https://www.hvivo.comCEO
Yamin Mohammed Khan
Description
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides preclinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
OPORF Financial Timeline
Browse a chronological timeline of hVIVO plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 8 Apr 2026
Upcoming earnings on 8 Sept 2025
Earnings released on 10 Apr 2025
EPS came in at $0.01 , while revenue for the quarter reached $31.94M , missing expectations by -3.15%.
Dividend declared on 10 Apr 2025
A dividend of $0.00 per share was announced, adjusted to $0.00. The dividend was paid on 11 Jun 2025.
Earnings released on 10 Sept 2024
EPS came in at $0.01 , while revenue for the quarter reached $47.08M , beating expectations by +4.59%.
Earnings released on 13 May 2024
EPS came in at $0.02 surpassing the estimated $0.01 by +156.93%, while revenue for the quarter reached $37.94M , beating expectations by +4.75%.
Dividend declared on 9 Apr 2024
A dividend of $0.00 per share was announced, adjusted to $0.00. The dividend was paid on 20 May 2024.
Earnings released on 30 Jun 2023
EPS came in at $0.01 , while revenue for the quarter reached $34.57M , missing expectations by -5.11%.
Dividend declared on 25 Apr 2023
A dividend of $0.01 per share was announced, adjusted to $0.00. The dividend was paid on 9 Jun 2023.
Earnings released on 31 Dec 2022
EPS came in at -$0.00 , while revenue for the quarter reached $37.45M , beating expectations by +0.86%.
Earnings released on 30 Jun 2022
EPS came in at $0.00 , while revenue for the quarter reached $21.86M .
Earnings released on 31 Dec 2021
EPS came in at -$0.00 , while revenue for the quarter reached $20.12M .
Earnings released on 30 Jun 2021
EPS came in at $0.00 , while revenue for the quarter reached $30.32M .
Earnings released on 31 Dec 2020
EPS came in at -$0.01 , while revenue for the quarter reached $18.40M .
OPORF Stock Performance
Access detailed OPORF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.